Personalized dosing of cancer or infection medicines in children
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial looks at how to adjust the dose of cancer medicines and/or anti-infection medicines in children who have blood-related cancers. The goal is to make dosing fit each child’s needs while they receive standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has a blood or bone-marrow cancer (a hematologic neoplasm) diagnosis
- Your child is already receiving cancer-fighting medicines and/or anti-infection (antibiotic) medicines as part of routine care
- Your child is expected to live at least through the full planned treatment cycle (not less than the cycle)
- Your child has no other major health or study-related reason the research team feels would make the trial unsafe or unsuitable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
This trial tests a way to treat certain blood cancers using a stem cell transplant from a partially matched (haploidentical) donor. It aims to make the transplant safer and reduce the chance of the immune reaction that can follow transplant, using post-transplant cyclophosphamide and bortezomib.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
This early-phase trial tests a treatment plan that uses results from genetic testing of your tumor to choose the best targeted therapy. It may help people whose cancer has come back or does not respond to standard treatment by matching treatment to specific tumor changes.
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
Hear when a new Hematological Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.